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Introduction: Timely communication about life
expectancy and end-of-life care is crucial for
ensuring good patient quality-of-life at the end of life
and a good quality of death. This article describes the
protocol for a multisite randomised controlled trial of a
nurse-led communication support programme to
facilitate patients’ and caregivers’ efforts to
communicate about these issues with their
healthcare team.
Methods and analysis: This NHMRC-sponsored trial
is being conducted at medical oncology clinics located
at/affiliated with major teaching hospitals in Sydney,
Australia. Patients with advanced, incurable cancer and
life expectancy of less than 12 months will participate
together with their primary informal caregiver where
possible. Guided by the self-determination theory of
health-behaviour change, the communication support
programme pairs a purpose-designed Question Prompt
List (QPL—an evidence-based list of questions
patients/caregivers can ask clinicians) with nurse-led
exploration of QPL content, communication challenges,
patient values and concerns and the value of early
discussion of end-of-life issues. Oncologists are also
cued to endorse patient and caregiver question asking
and use of the QPL. Behavioural and self-report data
will be collected from patients/caregivers approximately
quarterly for up to 2.5 years or until patient death, after
which patient medical records will be examined.
Analyses will examine the impact of the intervention on
patients’ and caregivers’ participation in medical
consultations, their self-efficacy in medical encounters,
quality-of-life, end-of-life care receipt and quality-of-
death indicators.
Ethics and dissemination: Approvals have been
granted by the human ethics review committee of
Royal Prince Alfred Hospital and governance officers
at each participating site. Results will be reported in
peer-reviewed publications and conference
presentations.
Trial registration number: Australian New Zealand
Clinical Trials Registry ACTRN12610000724077.
INTRODUCTION
Despite treatment advances, cancer often
remains a lethal disease. Disease progression,
patterns of decline and death are somewhat
predictable. Knowing one’s life expectancy
and planning care may afford opportunities
to prepare for the end of life (EOL) and
ensure care is consistent with patients’
values. Thus timely doctor/patient communi-
cation about prognosis and EOL issues is
vital.
Advance Care Planning (ACP) can guide
such communication. This process involves
discussion between a patient, their family
and clinicians to clarify and reflect on values,
treatment preferences and goals to develop a
shared understanding of how EOL care
should proceed.1 Discussing the patient’s
prognosis often forms a component of ACP.
This can clarify the timing and progression
of the patient’s decline and focus communi-
cation on how to balance goals of care. Such
Strengths and limitations of this study
▪ Encourages early discussion of prognosis and
end-of-life care.
▪ Novel combination of previously successful
interventions.
▪ Addresses all facets of self-determination theory
of health behaviour change.
▪ Targets multiple stakeholders.
▪ Rigorous study design utilising objective and
self-report data.
▪ Challenging to enforce endorsement of question
asking and Question Prompt List.
▪ Doctors do not receive comprehensive training in
responding to patient and caregiver questions.
▪ Intervention effect may not be fully captured in
single recorded consultation.
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discussions may reduce aggressive EOL medical care
and associated costs,2 increase early hospice referral,3
increase patient and caregiver satisfaction with care and
improve quality of life (QOL) and survival.4 5
This study is a randomised controlled trial (RCT) of a
nurse-led communication support programme (CSP) for
patients with advanced cancer and their primary infor-
mal caregiver. It is structured around a purpose-
designed Question Prompt List (QPL) highlighting the
value of early discussion of prognosis and EOL care.
The intervention seeks to improve communication
between patients, caregivers and oncologists regarding
these issues and open dialogue regarding ACP. This
article describes the rationale, evidence base and theor-
etical foundations and structure of the CSP, together
with details of study outcomes, hypotheses, measures
and administration protocols. Planned analyses, ethical
considerations and dissemination will also be discussed.
Communication about prognosis and EOL issues
Communicating about prognosis and EOL issues can be
challenging for doctors and patients. Doctors’ avoidance of
life-expectancy discussions is common,6 often for fear of
destroying hope or the therapeutic relationship.7 Patients’
readiness to discuss such issues is variable, and depends on
factors including degree and length of exposure to their
disease, having time to adjust to the cancer diagnosis,
coping style and spirituality.8 Death anxiety may also
trigger defence mechanisms such as denial or avoidance to
minimise anxiety and distance the mortality threat.9–13
Consequently, doctors and patients may ‘collude’ to avoid
these discussions.14 Communication about EOL care often
first occurs near death during acute hospital admissions,15
when critical decisions about chemotherapy and aggressive
life support may have been made. Research suggests as few
as 14% of doctors know patients’ preferences regarding
pain management or place of death,16 and many patients
receiving palliative chemotherapy do not understand its
non-curative intent.17 Hence, such discussions can be too
late or of poor quality.
Evidence suggests that EOL discussions do not
increase anxiety18 19 and a lack of information may
heighten anxiety by raising patients’ suspicions that
doctors are withholding potentially frightening informa-
tion.19 20 While the majority of patients with incurable
cancer indicate they want prognostic and EOL care dis-
cussions,21 22 prognostic information is not universally
desired. Eliciting preferences can be complex and may
impact subsequent EOL care discussions although
patients’ EOL priorities often relate to effective commu-
nication. One study found that patients’ highest ranked
attributes of a good death included to ‘have a nurse with
whom one feels comfortable’, ‘know what to expect
about one’s physical condition’, ‘have someone who will
listen’, ‘trust one’s physician’, ‘have physician with whom
one can discuss fears’, ‘know that one’s physician is com-
fortable talking about death and dying’ and ‘feel pre-
pared to die’.23
Self-determination theory
An ethical imperative to open prognostic disclosure and
early EOL discussions is the principle of patient auton-
omy; that patients have the right to information about
their body and to contribute to decisions about their
medical care if they wish.24 The self-determination
theory of health-related behaviour change25 26 suggests
that autonomy is not only a basic human right, but that
meeting patients’ needs for autonomy, as well as for
competence and relatedness, enhances engagement in
care and maintenance of outcomes. Thus it is critical to
address patient and health professional barriers to EOL
communication, and to involve patients in tailoring com-
munication to best suit their needs.
Caregiver involvement
Family caregivers play a crucial role in the EOL care of
patients with advanced disease. Beyond providing physical
support, caregivers may act as medical decision surrogates
in a formal or informal capacity. Caregivers often do not
receive sufficient information regarding patient disease
status and prognosis from clinicians or discuss EOL care
preferences with patients and adequately prepare for sur-
rogate decision-making.27 This may hinder their ability to
make appropriate decisions regarding patient care.
Patients and caregivers also have somewhat divergent
information needs as the patient’s illness progresses, with
caregivers preferring more information and patients less.27
Appropriate EOL communication has also been associated
with better caregiver bereavement outcomes, less aggres-
sive patient treatment patterns and better QOL.3
Interventions to improve communication at the EOL
Evaluations of interventions to improve communication
with patients with advanced cancer have focused on
impacting patient or doctor behaviours separately or the
shared health communication environment. Few have
targeted or involved caregivers or family. Patient inter-
ventions have generally focused on providing tools, such
as QPLs, or training to increase assertiveness in meeting
communication needs. QPLs are evidence-based lists of
questions grouped into themes, which patients and/or
caregivers are encouraged to ask their clinician. QPLs
are often valued for showing the range of topics for dis-
cussion, assisting with question formulation and high-
lighting clinicians’ willingness to discuss all subjects.28–30
Our group evaluated the impact of giving patients a
QPL in the first, second or third palliative care consult-
ation in an RCT.29 Compared with controls, patients and
caregivers who received a QPL asked twice as many ques-
tions, particularly about prognosis and EOL issues, pro-
vided the doctor endorsed question asking. Intervention
patients’ question asking increased by 1.6 times with any
endorsement of question asking from the doctor, and by
5.8 times if there was more extensive endorsement.
Fewer intervention patients had unmet information
needs about the future, the area of greatest unmet infor-
mation need. No intervention effect was observed for
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satisfaction with care or anxiety and outcomes such as
patient QOL, actual care and caregiver outcomes were
not assessed.
In another study, patients with a QPL endorsed by
their clinician were significantly less anxious after the
consultation and recalled significantly more information
about treatment issues and side effects than patients
with a QPL alone.31 Notably, when physicians did not
endorse the QPL, patients asked no more questions
than controls highlighting the role of clinicians in deter-
mining the success of patient interventions.
Doctor interventions typically focus on communica-
tion skills training. Back et al32 reported in a pre–post
study that communication skills training for oncology
fellows improved skills in breaking bad news and discuss-
ing transitions to palliative care. The impact on patients
of these changes was not assessed and the intervention
was a 4-day residential workshop, which may not feasible
for many busy clinicians.
Interventions targeting the shared health communica-
tion environment have evaluated the efficacy of a commu-
nication broker who, trusted by the oncologist and patient,
can help both parties in clarifying and communicating
assumptions and expectations. The seminal SUPPORT
study33 involved an RCT of a nurse-led intervention for
hospitalised patients with life-limiting illnesses including
advanced cancer. A trained nurse had several contacts
with patients, family, physicians and hospital staff to elicit
patient preferences, improve understanding of outcomes
and facilitate ACP. No improvement in patient–physician
communication or outcomes including incidence or
timing of DNR orders, physicians’ knowledge of patients’
resuscitation preferences, days in intensive care unit,
mechanical ventilation receipt, use of hospital resources
or patients being comatose before death was seen. Specific
communication tools to assist patients were not utilised
and physicians were not directly targeted with communica-
tion skills training or question-asking endorsement cues,
which may have reduced its impact.
In summary, external prompts normalising and placing
EOL issues on the consultation agenda may be beneficial,
together with efforts to improve patients’ and caregivers’
self-efficacy in meeting their information and involve-
ment needs. Providing patients with cancer and care-
givers with a preconsultation QPL may be helpful,
combined with improving doctors’ endorsement of ques-
tion asking. An outside communication broker coaching
patients and caregivers to clarify their questions and con-
cerns, improving their skills in requesting information
during consultations and empowering them to do so may
further improve communication. Given time burdens
inherent in residential training workshops for clinicians
and the potential for QPLs with endorsement to improve
patients’ ability to get their information needs met, a
doctor-endorsed QPL amplified by nurse-led communi-
cation support and information about EOL issues has
promise. This powerful combination has never previously
been evaluated.
Current investigation
Building on this literature, an intervention targeting
patients and caregivers with the aim to improve doctor–
patient–caregiver communication about prognosis and
EOL issues will be evaluated. The intervention targets
patients and caregivers prior to patients becoming critically
ill and unable to communicate their preferences and
wishes. The intervention seeks to influence the three areas
identified by self-determination theory as being crucial for
patients to enact and maintain ACP behaviours25 26 34: (1)
‘Autonomous Motivation’ to discuss prognosis and EOL
care preferences; (2) ‘Competence’ to undertake such dis-
cussions and (3) social support or ‘relatedness’ to partici-
pate in such discussions.
The goal of the intervention is to impact on (1) com-
munication, (2) care, QOL and quality of death and (3)
satisfaction outcomes. We hypothesise that the interven-
tion will:
▸ Increase patients’ and caregivers’ self-reported per-
ceived efficacy scores in communication with their
oncologist (H1a);
▸ Increase the number of questions/cues/concerns
expressed by patients and caregivers during a
follow-up oncology consultation regarding the issues
targeted in the QPL and overall (H1b);
▸ Increase concordance between (1) patients’ and care-
givers’ self-reported preferred level of information
receipt and involvement in decisions about care and
(2) their self-reported actual level of these factors
during a follow-up oncology consultation (H1c);
▸ Increase concordance between (1) patients’ self-
reported hopes for treatment and preferences regard-
ing EOL medical care and (2) caregivers’ self-reported
understanding of patients’ hopes and preferences
(H1d);
▸ Decrease the number of high impact EOL medical
interventions that patients indicate they wish to
receive and increase the number of relevant others
that patients will report having having communicated
with regarding their preferences (H2a);
▸ Decrease the number of emergency room visits and
high-impact medical interventions received by
patients at the recruiting hospital during the last
month of life (H2b);
▸ Increase patients’ quality-of-death scores as rated by
their caregiver (H2c);
▸ Increase patients’ and caregivers’ self-reported QOL
scores (H2d);




This study is a parallel group RCT conducted at medical
oncology clinics based at or affiliated with major hospi-
tals in the Sydney, Australia. It will evaluate the effects of
an intervention designed to improve communication
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between patients with advanced cancer, their primary
informal caregivers and their oncologist. The interven-
tion is intended for use when patients have a year or less
to live.
Patients and caregivers participate as dyads. Patients
can participate without a caregiver; however caregivers
cannot participate without a corresponding patient par-
ticipant. Patients and caregivers complete questionnaires
following consent, are randomised and participate in
intervention or control conditions, allow one regular
oncology follow-up consultation to be audio recorded,
and complete follow-up questionnaires at regular inter-
vals until the patient’s death (see figure 1). Additionally,
patients’ medical records are reviewed and caregivers
are invited to participate in a structured interview follow-
ing the patient’s death.
Participants
Currently practicing medical oncologists at participating
hospitals are requested to refer consecutive eligible
patients to the research team after briefly mentioning
the goals of the study and seeking verbal approval to
release their contact details.
Patients are eligible if they have been diagnosed with
any type of cancer and their medical oncologist believes
they have a life expectancy of between 2 and 12 months.
Caregivers are eligible if they are identified as the
primary, informal providers of care to a patient partici-
pating in the trial. Patients and caregivers must read and
speak English well enough to be interviewed and com-
plete questionnaires without the aid of an interpreter,
be over the age of 18 years and be capable of giving
informed consent. Patients and caregivers will be
excluded if they do not speak English or have significant
psychological morbidity or cognitive impairment.
Recruitment
Oncologist referrers are informed about the study at
departmental meetings or via a letter from the study
investigators. Those who agree to refer are given all
necessary information and consent forms, questionnaires
and referral documents. Referrers identify patients who
fit the study inclusion criteria, inform them about the
study during a consultation, provide relevant study
information and refer interested patients to a research
nurse following the consultation. Referrers will receive
regular prompts from study personnel to review their
patient lists for potentially suitable participants and such
opportunities will be used to discuss the ongoing chal-
lenges with referral and potential solutions. Regular
study newsletters including updates on recruitment
targets will also be sent to referrers to foster engagement
in the study.
The research nurse explains the study in further detail
and provides patients who agree to participate with
information and consent forms, baseline questionnaires
and a reply paid envelope to return completed study
documents. If the research nurse is not present during
consulting hours, the referrer sends the patient’s contact
details to the research team after obtaining verbal
consent for the referral. A member of the research team
then contacts the patient to explain the study and post
the study documents to those willing to participate. The
patient is requested to complete and return the forms as
soon as possible by reply paid post.
Patients are told that caregivers are encouraged to par-
ticipate and asked to identify the family member or
friend who assists them most often with their healthcare.
If a caregiver is present at the point of referral and the
patient is willing for their caregiver to be involved, infor-
mation about participation is provided. If no caregiver is
present at the point of referral but a caregiver is nomi-
nated, a member of the research team contacts the care-
giver by phone to explain the study, obtain consent and
post questionnaires.
Randomisation
Patients and caregivers are randomised as dyads, with
the patient as the unit of randomisation, stratified by the
oncologist. Patients are randomised alone if they do not
nominate a caregiver or if their nominated caregiver
declines. Patients and dyads are randomised immedi-
ately following receipt of consent and baseline data.
A computer-generated random number table is used
to generate 1 : 1 balanced randomisation code blocks for
each referring oncologist. Odd numbers will indicate
control arm assignment and even numbers will indicate
intervention arm assignment. Each code is placed in an
Figure 1 Study diagram.
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individual, sequentially numbered, opaque envelope.
Once consent and baseline questionnaires are received,
the research manager, blinded to participant identity,
opens the next envelope in sequence for the referring
oncologist to determine randomisation. The research
staff member responsible for contacting the participant
is informed of the outcome and initiates the next steps
of participation.
Intervention
Nurse role and training
The intervention places primary emphasis on communi-
cation about prognosis, general EOL issues and ACP.
The programme is delivered by a senior nurse who has
experience in cancer care and highly developed commu-
nication skills, affording them the best opportunity to
understand and relate to the experiences of patients
with advanced cancer. The role of the nurse is to assist
and empower patients and their caregivers to communi-
cate with their healthcare team regarding goals, wishes,
needs, concerns and questions about life expectancy
and EOL issues. The nurse will not answer questions
about the patient’s health or individual situation but will
encourage them to direct those questions to their
healthcare team.
The nurse receives specific training to deliver the pro-
gramme. This training involves review of a standardised
training manual describing the rationale, goals and spe-
cific tasks involved in completing the intervention, fol-
lowed by role-play exercises conducted with a simulated
patient and directed by a researcher well versed in such
training methods. Role-play exercises aim to progres-
sively build confidence and competence in delivery and
adherence to the intervention protocol. Training takes
approximately 30–40 h per nurse, depending on the trai-
nee’s level of existing communication skills.
The study manager will regularly review recordings of
sessions delivered by each trained nurse to ensure adher-
ence to the programme delivery protocol. Any problems
with adherence or programme delivery will be discussed
at fortnightly meetings between the trained nurses and
study manager. Nurses will also be offered the opportun-
ity for debriefing and peer supervision with a senior
psychologist as necessary.
Communication Support Programme
The CSP was informed by the self-determination theory
of health-related behaviour change. In line with previous
research describing ACP as a process of health behav-
iour change,34 discussion of prognosis, EOL care and
ACP were characterised as health-related behaviours
impacting EOL QOL. The intervention seeks to influ-
ence: (1) ‘Autonomous Motivation’ to discuss prognosis
and EOL care preferences—by helping participants
identify the value and importance of such discussions,
(2) ‘Competence’ to undertake such discussions—by
giving participants the skills and tools to engage in dis-
cussions and overcome barriers to planning care and (3)
social support (relatedness) to participate in such discus-
sions—by cueing oncologists to endorse question asking
and use of the QPL.
Two nurses have been trained to deliver the interven-
tion, which consists of two sessions: (1) a face-to-face
meeting and (2) a telephone booster session.
Face-to-face meetings include a QPL designed for
patients with advanced, incurable cancer and their
primary informal caregivers.35 This includes questions
related to factors identified as important at EOL by
patients, family, physicians and clinicians23 and sug-
gested and developed by an expert panel. These include
prognosis and disease status, treatment options and deci-
sions, palliative care, lifestyle changes, support for the
patient and their family, ACP and questions specifically
for caregivers. Face-to-face meetings are delivered at
cancer treatment centres and attended by patient parti-
cipants, with primary informal caregiver participants
also attending where possible. Prescribed face-to-face
meeting content is presented in table 1.
Telephone booster sessions aim to amplify the content
of the face-to-face meeting and include review of what
was discussed in the patient’s last medical oncology con-
sultation, exploration of unaddressed information needs
and concerns and guidance on how to prepare for
future consultations using the QPL. Booster sessions are
scheduled for a time convenient to the patient between
1 and 2 weeks after the first oncology consultation fol-
lowing the face-to-face meeting. Caregivers are not
included in this portion of the intervention. Prescribed
session content is presented in table 2.
Face-to-face meetings and telephone booster sessions
will be discontinued if patients or caregivers become sig-
nificantly distressed at any time during the session or
request that the session be stopped. Where necessary,
participants will be referred to support services or coun-
selling at participating hospitals and clinics. All such
events will be recorded in an adverse events log and will
be reported in accordance with the adverse event report-
ing procedures specified by the relevant ethics and gov-
ernance committees for each site.
Oncologists are cued to endorse question asking
during audio-taped follow-up consultations and to recog-
nise the QPL and endorse participants’ efforts to use it.
An example of how oncologists could endorse question
asking and the QPL is presented below:
I believe you met with (name of nurse) a week or so ago
and received a booklet with some suggestions about
helpful questions to ask. It’s important that you feel
you’ve got all the information you want. It’s not unusual
to leave an appointment and realise that you’ve forgotten
to ask about something important and I want you to
remember that I’m happy to answer any questions you
have as best as I can. They could be questions from the
booklet or something else that you’ve thought of or even
something we covered today. And don’t worry if it’s too
big to get through today; we can make sure we discuss it
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further at a future appointment. So, do you have any
questions you’d like to ask?
Data collection
Assessment timing and behavioural data collection
Intervention and control participants are randomised
after completing baseline questionnaires. Intervention
arm participants receive the CSP 1–2 weeks before a
regular oncology follow-up consultation. Intervention
arm participants complete measures at the conclusion of
the face-to-face session. Following the intervention, or
baseline assessment for control patients and dyads, parti-
cipants’ next oncology consultation is audio taped for
transcription and analysis. Participants complete ques-
tionnaires approximately 1 month after the consultation
is audio taped, and every 3 months until the patient’s
death. Two months after the patient dies, the caregiver is
invited to complete a telephone interview and patients’
medical records are accessed for review (see figure 1).
Patient questionnaire measures
Table 3 lists all study outcomes, questionnaires and
timing of administration for patient participants.
Demographic details collected from patients include age,
gender, education and work details, primary diagnosis,
disease-directed treatments received, medical or allied
health training, ethnicity and religious affiliations.
Communication self-efficacy is measured with the Perceived
Efficacy in Patient Physician Interactions (PEPPI) scale.36
QOL is measured using the Functional assessment of
cancer therapy—general questionnaire (FACT-G)37 and
the McGill QOL scales.38 Preferences for information and
involvement in decisions about care are measured using the
Degner Control Preference Scale39 and two items from
the Cassileth Information Styles Questionnaire.40
Achievement of preferences for information and involvement in
decisions about care are measured using modified versions
of these scales worded to reflect achievement of decision
and information preferences. Hopes for treatment are
assessed using a purpose-designed free-response question
Table 1 Communication support programme content—sections and specific goals of the face-to-face meeting
Section Specific goals
1 Introduction and discussing the meeting
agenda
▸ Explain the reason and goals of the session
▸ Outline what will be discussed during session
▸ Highlight procedural matters (eg, recording of the session)
▸ Offer to answer questions
2 Getting to know the patient and their
caregiver
▸ Discuss patients’ and caregivers’ cancer journey
▸ Discuss impact of cancer on life
▸ Discuss goals, wishes and concerns in light of cancer
3 Introducing the question prompt list ▸ Give participants the QPL
▸ Explain the purpose and how to use QPL
▸ Highlight prognosis and end-of-life care planning content
4 Exploring the question prompt list and
healthcare communication
▸ Discuss QPL content in detail
▸ Explore questions, concerns and barriers to using QPL
▸ Explore experiences of communicating with the oncologist
▸ Provide additional information and discussion about ACP (DVD and
Information sheet) and Enduring Guardianship (Australian Guardianship
Tribunal material)
5 Wrapping up and nominating questions
for the next consultation
▸ Assist patient to plan for the next consultation by choosing questions they
may like to ask and discussing how and when to ask questions
▸ Offer to answer questions
ACP, Advance Care Planning; QPL, Question Prompt List.
Table 2 Communication support programme content—sections and specific goals of the telephone booster session
Section Specific goals
1 Review of last oncology consultation ▸ Explore what questions were asked in consultation
▸ Explore what information was received in consultation
▸ Explore success or otherwise of communication strategies developed in
face-to-face meeting
2 Explore new or outstanding information
needs and concerns
▸ Explore unaddressed questions and concerns
▸ Explore new questions and concerns
3 Planning for future consultations ▸ Assist patient in planning for next consultation by choosing questions they
may like to ask and discussing how and when to ask questions
▸ Reiterate how to use QPL and how to plan for future consultations
▸ Offer to answer questions
QPL, Question Prompt List.
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probing realistic hopes given the patient’s current state of
health. Preferences for future interventions are measured with
a purpose-designed scale asking patients to indicate
whether they want, do not want or are unsure about
whether they want each of six common high-impact EOL
medical interventions. Patients are also asked to indicate
the reason for their preference and who they have dis-
cussed their preference with for each intervention.
Acceptance of disease is measured using the Peace,
Equanimity and Acceptance in the Cancer Experience
Scale (PEACE).41 Patients’ understanding of their prognosis
is measured using a purpose-designed questionnaire
asking patients to indicate the location and spread of
their disease as they understand it and to indicate what
treatments may still be beneficial to them. They are also
asked to give a free response indicating what their doctor
has told them about their life expectancy and indicate on
a 12-point Likert scale the percentage chance (in 10%
increments) that they will live one and five further years,
with options to refuse to answer or indicate that they are
unsure. Lastly, patients are asked to rate their doctor’s com-
munication skills and manner during consultations using a
purpose-designed scale. Following each patient’s death,
their medical records will be accessed and purpose-
designed data extraction will be performed to examine
evidence of active, cancer-focused treatment, emergency
intervention and palliative management received during
the final month of life (see table 4).
Caregiver questionnaire measures
Table 5 lists all study outcomes, questionnaires and
timing of administration for caregiver participants.
Demographic details collected from caregivers include rela-
tionship to the patient participant, age, gender, educa-
tion, work details, receipt of caregivers’ benefits, medical
or allied health training, ethnicity and religious affili-
ation. Communication self-efficacy is measured with an
adapted version of the PEPPI scale,36 reflecting the care-
giver/physician relationship rather than the patient/
physician relationship. QOL is measured using the SF-36
V.2.42 Preferences for information and involvement in decisions
about patient care are measured using an adapted Degner
Control Preference Scale39 and two items from the
Cassileth Information Styles Questionnaire,40 reflecting
the caregiver’s role in making decisions about patient
care. Achievement of preferences for information and involve-
ment in decisions about care is measured using modified
versions of these scales worded to reflect achievement of
decision and information preferences. Understanding of
patients’ hopes for treatment is assessed using a free-
response question probing caregivers’ understanding of
the patient’s realistic hopes given their current state of
health. Understanding of patients’ preferences for future inter-
ventions is measured with a purpose-designed scale,
asking caregivers to indicate whether they believe that
the patient wants, does not want or if they are unsure if
the patient wants each of six common high-impact EOL
medical interventions. Caregivers are also asked to indi-
cate their beliefs about the patient’s reasons for their
Table 3 Patient questionnaire measures and administration timing
Outcome Measure Baseline Preconsultation Postconsultation
Quarterly
follow-up
Demographics Purpose designed X
Medical communication self-efficacy PEPPI X X* X X
Quality-of-life FACT-G, MQOL X X X
Topics discussed in consultations Purpose
Designed
X X X
Information and involvement DCPS, CISQ X X†
Disease and prognostic
understanding
Purpose designed X X
End-of-life treatment preferences Purpose designed X X X
Hopes for treatment Purpose designed X X X
Acceptance and adjustment to cancer PEACE X X X
Consultation experiences Purpose designed X
Satisfaction Purpose designed X* X*
*Completion by intervention arm only.
†Modified version of DCPS and CISQ reflecting achievement of decision/information preferences.
CISQ, Cassileth information styles questionnaire; DCPS, Degner control preferences scale; FACT-G, Functional assessment of cancer
therapy—general questionnaire; MQOL, McGill Quality of Life questionnaire; PEACE, Peace, equanimity, and acceptance in the cancer
experience questionnaire; PEPPI, Perceived efficacy in patient–physician interactions scale.





















QODD, Quality of death and dying questionnaire.
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preferences and who the patient has discussed their pre-
ferences with for each intervention. Caregivers’ under-
standing of the patients’ prognosis is measured using a
purpose-designed questionnaire, asking caregivers to
indicate the location and spread of the patient’s disease
as they understand it and to indicate what treatments
they believe may still be beneficial to the patient. They
are also asked to give a free response indicating what the
doctor has told them about the patient’s life expectancy
and indicate on a 12-point Likert scale the percentage
chance (in 10% increments) that the patient will live
one and five further years, with options to refuse to
answer or indicate that they are unsure. Following the
patient’s death, caregivers are invited to participate in a
structured telephone interview, the Quality Of Death
and Dying scale (QODD)43 to elicit their views on the
quality of the patient’s death, and their satisfaction with
care at that time (see table 4).
Coding of audio-taped consultations
Audio-taped follow-up oncology consultations are tran-
scribed and coded using a purpose-designed, manua-
lised coding scheme allowing content to be utilised in
quantitative analyses. For each transcript, all patient and
caregiver utterances indicating a need for information
or discussion are identified and coded. Summaries of
coded utterances are produced for each consultation
(see table 6).
Planned analyses
The primary self-reported communication outcome is
patients’ medical communication self-efficacy, mea-
sured by the PEPPI. The primary behavioural commu-
nication outcome is the number of questions, cues
and concerns raised by the patient and caregiver
during the audio-taped follow-up oncology
consultation. Secondary outcomes include all other
questionnaire measures completed by patients and
caregivers, details of patient medical care in the last
month of life revealed by medical records review and
the quality of death and dying interview completed
by caregivers.
Analysis will be by intention to treat, using all available
data from randomised participants based on group
assignment. Initial analyses will examine whether ran-
domisation produced comparable groups in terms of
age, gender, education and disease factors. Confounding
variables will be accounted for in subsequent analyses.
The primary self-report communication outcome will be
tested based on the difference between patients’ score
on the PEPPI at baseline and postintervention time
points in the two study arms. The primary behavioural
communication outcome will be tested based on counts
of questions, cues and concerns expressed by patients
and caregivers during the recorded consultation in the
two study arms. Primary outcomes will be analysed for
group differences using a mixed model with the oncolo-
gist as a random effect, to allow for comparison of con-
sultations involving recipients of the CSP or control
conditions by the same oncologist. Secondary self-report
outcomes will be analysed using similar methods. Hopes
for treatment and prognostic understanding of free-
response questions will be categorically coded, allowing
for the inclusion of variables in the secondary analyses,
and analysed in depth using qualitative methods at a
later date along with qualitative data from recorded con-
sultations and intervention sessions. As missing data may
likely have the potential for substantial attrition in a pal-
liative population,44 the nature of missing data will be
examined and addressed using methods such as listwise
deletion, weighted GEE (WGEE) or multiple imputation
as appropriate.
Table 5 Caregiver questionnaire measures and administration timing






Medical communication self-efficacy PEPPI (adapted) X X* X X
Quality of life SF-36 V2 X X X
Information and involvement DCPS, CISQ
(adapted)
X X†


















* denotes completion by intervention arm only.
† denotes modified version of DCPS and CISQ reflecting achievement of decision/information preferences.
CISQ, Cassileth information styles questionnaire; DCPS, Degner control preferences scale; PEPPI, Perceived efficacy in patient-physician
interactions scale; SF-36 V2, SF36 health survey V.2.
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Sample size
Power calculations were based on communication
during the single audio-taped oncology follow-up con-
sultation for each patient. With a sample of 14 oncolo-
gist referrers and 10 patients per referrer (140 patients
total) there will be a 98% power to detect a difference
of 1.5 EOL-related questions, cues or concerns during
the audio-taped consultation. This calculation assumes
an average of 0.5 EOL-related questions, cues or con-
cerns per consultation in the control group and two
EOL-related questions, cues or concerns in the treat-
ment group. This sample also gives 84% power to detect
an effect size of 0.5 on the patient medical communica-
tion self-efficacy scale (PEPPI).
ETHICS AND DISSEMINATION
Ethical review
This study is being conducted in accordance with the
National Health and Medical Research Council of
Australia National Statement on Ethical Conduct in
Human Research (2007). All participants will give
informed consent to participate and may withdraw at
any time without impacting their treatment or relation-
ship with the hospital or their clinical team. Collected
data will be de-identified and stored securely for a
minimum of 7 years. Accepted adverse event monitoring
procedures will be followed and appropriate referral to
psychological and support services at participants’ treat-
ing hospital will be made as required.
Relevance and dissemination
This study will be among the first to evaluate an inter-
vention simultaneously targeting patients and care-
givers to improve communication about prognosis and
EOL issues, while cuing oncologists to endorse ques-
tion asking and the QPL. The design of the CSP
seeks to recognise and address the challenging nature
of such discussions and the limitations of previous
studies designed to improve EOL communication.
Strengths include the targeting of multiple stake-
holders and the focus on empowering patients and
caregivers through careful preparation by a trained
nurse, endorsement by their medical oncologist and
provision of a specific tool designed to support them
in clarifying their questions and concerns. The study
will assess whether this intervention increases patients’
and caregivers’ self-efficacy in asserting their informa-
tion needs, and whether this translates into increased
expression of information needs and thus more infor-
mation from their oncologist. Provision of tailored
information may improve patient and caregiver under-
standing of prognosis,45 and result in a greater likeli-
hood of effective and timely ACP with corresponding
improvements in QOL outcomes.2–5 Ultimately, it is
hoped that this intervention will result in patients
receiving EOL care that is more concordant with
their preferences and values.
The brevity of the intervention, together with the
incorporation of multiple previously successful interven-
tion types are strengths that may yield a substantial
impact. This study has the potential to provide a mech-
anism for assisting patients, health professionals and
caregivers in communicating about, understanding and
acting on patient preferences to ensure quality EOL
care. We plan to publish the main trial outcomes related
to communication and satisfaction in a single paper,
with additional papers exploring the impact of the inter-
vention and any changes in communication on care,
QOL and quality of death. Further in-depth analyses of
the implementation of this intervention and responses
to its content will also be published and findings will be
presented at various national and international
conferences.
Table 6 Consultation coding scheme




Follows QPL content Yes/no
QPL item Indicate QPL item number
Wording identical Yes/no
Wording of utterance Note exact wording of utterance
Topic area Indicate best applicable QPL-related or non-QPL-related area
(10 QPL and 9 non-QPL codes available)
Addressed by oncologist Yes—immediate response/yes—delayed response/no
Coded for overall consultation
Number of questions/cues/concerns Separately count of each utterance type for patient and caregiver
Total new issues raised Separately count for patient and caregiver
Total clarifications Separately count for patient and caregiver
Words spoken Separately count for patient, caregiver and oncologist
Consultation length Length in minutes and seconds
QPL, Question Prompt List.
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